https://www.statcounter.com/counter/counter.js
Web Analytics
Home » Posts tagged with » infliximab
Samsung Bioepis, C-Bridge Capital collaborate to develop and commercialize biosimilars in China

Samsung Bioepis, C-Bridge Capital collaborate to develop and commercialize biosimilars in China

Samsung Bioepis, a South Korean biopharma company, has signed a licensing agreement with private equity firm C-Bridge Capital to develop and commercialize next-generation biosimilars in China. The agreement covers Samsung Bioepis’ various biosimilar candidates like SB11 and SB12, which reference LUCENTIS (ranibizumab) and SOLIRIS (eculizumab), respectively, and also SB3, a biosimilar candidate referencing HERCEPTIN 3 […]

Amgen seeks FDA approval for infliximab biosimilar ABP 710

Amgen has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to Johnson & Johnson’s REMICADE (infliximab). ABP 710 is being studied as a biosimilar candidate to infliximab, which is an anti-tumor necrosis factor alpha (anti-TNF) monoclonal antibody. Infliximab has approval in several regions […]

Continue reading …